Journal
NATURE REVIEWS CANCER
Volume 10, Issue 1, Pages 9-22Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2748
Keywords
-
Categories
Funding
- US National Institutes of Health [CA50286, CA45726]
- NATIONAL CANCER INSTITUTE [R01CA045726, T32CA121938, R37CA050286, R01CA050286] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the alpha v beta 3 and alpha v beta 5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available